RBC Capital analyst Douglas Miehm raised the firm’s price target on Bausch + Lomb to $20 from $17 and keeps an Outperform rating on the shares ahead of its Q4 results. Currency headwinds in Q4 are expected to be lower than previously anticipated, but they will likely be offset by China-related factors where the lifting of zero-COVID policy resulted in increased cases and hospitalizations, the analyst tells investors in a research note. The firm adds that its higher price target is based on the re-rating in Bausch + Lomb’s key eye-care peers.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on BLCO:
- Bausch + Lomb names Brent Saunders as CEO, succeeding Joseph Papa
- FDA approves Bausch Lomb & Modulight’s ML6710i photodynamic laser
- Bausch + Lomb acquires AcuFocus, terms not disclosed
- Bausch + Lomb Novaliq announce GOBI trial met both co-primary endpoints
- Bausch + Lomb amends CEO separation agreement